Harmonized Global Registration of a Class II Hemostatic Valve in Six Key Markets

Overview

A US-based medical device manufacturer already held approvals for its Class II hemostatic valve in the United States, Canada, and the European Union. The company aimed to expand into six additional high-potential markets: Australia, Brazil, China, India, Pakistan, and Russia.

A harmonized regulatory approach was implemented to streamline the process, reduce duplication, and accelerate approvals across diverse regulatory environments.

Device Classification in Target Markets

Country	Classification
Australia	Class IIb
Brazil	Class IIb
China	Class II
India	Class C
Pakistan	Class C
Russia	Class IIb

Estimated Approval Timelines

• Australia: 2–3 months
• Brazil: 5–6 months
• China: 12–20 months
• India: 9–18 months
• Pakistan: 6 months
• Russia: 18 months

Five-Step Integrated Registration Strategy

1. Regulatory Intelligence
   Comprehensive collection of all regulatory requirements for the hemostatic valve in the six target countries.

2. Regulatory Strategy
   Development of a tailored registration plan for each market, including classification confirmation and timeline projections.

3. Dossier Preparation
   Creation of a single core dossier that satisfied requirements across all target markets.
   Priorities were aligned with commercial plans and any additional local testing needs.
   Risks and complexities were identified and mitigated in advance.

4. Dossier Submission and Approval
   Submission of the core dossier to the respective health authorities in each country.
   Support provided for any required local testing.
   Prompt responses to all authority queries ensured smooth progression to final approval.
   Efficient project management maintained consistent communication and timely submissions.

5. License Maintenance
   Ongoing post-approval support to keep licenses active and compliant in each market.

Key Benefits Achieved

• Early strategic planning aligned regulatory efforts with commercial priorities.
• Harmonized dossier significantly reduced preparation effort and timelines.
• One-stop regulatory support covered intelligence, strategy, submission, and maintenance.
• Expertise in harmonizing processes across regions delivered measurable efficiency gains.

This case demonstrates how a coordinated global strategy enables rapid and compliant expansion of Class II medical devices into multiple international markets while building on existing approvals.